We are live on ! Find out more
BBLG

Bone Biologics
BBLG

5 hedge funds and large institutions have $69.7K invested in Bone Biologics in 2024 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

25% more funds holding

Funds holding: 4 → 5 (+1)

0.46% more ownership

Funds ownership: 4.76% → 5.22% (+0.46%)

22% less capital invested

Capital invested by funds: $89.1K → $69.7K (-$19.5K)

Holders
5
Holders Change
+1
Holders Change %
+25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
2
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$54.5K
2
HF
HRT Financial
New York
+$28.8K
3
TRCT
Tower Research Capital (TRC)
New York
+$2.54K
4
MWA
MFA Wealth Advisors
Pennsylvania
+$661
5
Bank of America
Bank of America
North Carolina
+$20

Top Sellers

Rank Fund Capital Flow
1
AC
Armistice Capital
New York
-$78.8K
2
Wells Fargo
Wells Fargo
California
-$9

BBLG Hedge Fund Activity: Q2 2024 in Review

5 of the 6,938 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q2 2024, worth a combined $69.7K — down 22% from $89.1K a quarter earlier.

Buyers outnumbered sellers: 3 funds opened new BBLG positions and 2 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.

The largest buyer was UBS Group, adding an estimated $54.5K. The largest seller was Armistice Capital, exiting entirely with an estimated $78.8K sold.

  • 5 institutional investors held Bone Biologics (BBLG) as of Q2 2024, up from 4 in Q1 2024.
  • Funds reported $69.7K of Bone Biologics stock for Q2 2024, down 22% quarter-over-quarter.
  • 3 funds opened new Bone Biologics positions in Q2 2024 and 2 closed out, a net change of +1 holder.
  • The largest Bone Biologics buyer in Q2 2024 was UBS Group, an estimated $54.5K added.
  • The largest Bone Biologics seller in Q2 2024 was Armistice Capital, an estimated $78.8K sold.

Based on aggregated 13F filings for Q2 2024.